Novo Nordisk settles patent infringement lawsuit with Novartis

Shortly before a trial was meant to begin, Novo Nordisk and Sandoz have settled a patent infringement case concerning diabetes drug Victoza, meaning the generic drugmaker isn’t allowed to launch its intended copy version before June 2024.

Photo: George Frey/Reuters/Ritzau Scanpix

The two pharmaceutical firms, Novo Nordisk and Novartis-owned Sandoz, have come to an agreement out of court, meaning that Sandoz will hold off on the launch of its generic version of the Danish firm’s blockbuster insulin analog, Victoza (liraglutide), industry media Fierce Pharma writes.

The patent infringement lawsuit pertaining to Victoza, which was headed to Delaware federal court in April, is therefore closed.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs